INCHEON, South Korea - TelAve -- Eone-Diagnomics Genome Center (EDGC), a leading global genomics and precision medicine company headquartered in South Korea, is proud to announce that it has received official approval for the Clinical and Public Health Laboratory License from the California Department of Public Health (CDPH). This significant milestone enables EDGC's Incheon-based laboratory to legally accept and process clinical diagnostic samples from California and throughout the United States, under one of the most rigorous state-level regulatory frameworks in the country.

California is recognized for setting the highest standards for clinical laboratory operations in the U.S., and this approval reflects EDGC's ongoing commitment to excellence in laboratory medicine, regulatory compliance, and global clinical testing standards. With this license, EDGC becomes one of the few non-U.S. laboratories authorized to directly receive and test clinical samples from California, a state known for its stringent oversight in laboratory diagnostics.

More on TelAve News

• $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
• Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
• Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
• Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
• Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings

"This license is not just a regulatory achievement—it's a validation of EDGC's quality, integrity, and leadership in global genomics," said Dr. Min Seob Lee, Founder and CEO of EDGC. "We are honored to serve physicians and patients in California and across the U.S., delivering advanced clinical testing in genomics and precision medicine."

EDGC currently provides CLIA-certified and CAP-accredited testing services to over 30 countries worldwide, offering a broad portfolio of high-precision diagnostics including:

• Non-Invasive Prenatal Testing (NIPT)
• Newborn Genetic Screening
• Oncology Liquid Biopsy
• EpiClock™ Biological Age and Longevity Testing
• Disease Risk Assessment
• Comprehensive Genetic Screening Panels

This California license enhances EDGC's ability to partner with U.S. hospitals, biotech firms, and research institutions, and accelerates its mission to make personalized genomic medicine accessible on a global scale.

More on TelAve News

• AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
• The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
• Ace8 Launches Cutting-Edge Observability Service to Empower Modern IT Operations
• AceMQ Unveils Advanced Containerization Solutions to Accelerate Digital Transformation
• $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN

For more information or to inquire about EDGC's clinical services in the U.S. and internationally, please visit www.edgc.com.

About EDGC
Eone-Diagnomics Genome Center (EDGC) is a global leader in genomics and precision diagnostics, offering next-generation sequencing, bioinformatics, and AI-integrated testing platforms. With headquarters in Incheon, South Korea and global partnerships across Asia, Europe, and the U.S., EDGC is at the forefront of the DNA-driven revolution in healthcare.